Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 18/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 18/20 | 0.61 |
| ▸ | GRN | P28799 | 1/20 | 0.60 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.60 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878985 | 1.00 | TAS1R3 (0.61) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL3435364 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL16604671 | 0.87 | GRN (0.78) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL16604673 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL3436306 | 0.87 | GRN (0.78) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL10029221 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1GRNSORT1LNPEP | |
| SCHEMBL13091305 | 0.86 | TAS1R3 (0.62) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL701392 | 0.85 | TAS1R3 (0.76) | TAS1R3TAS1R1GRNSORT1 | |
| SCHEMBL10062587 | 0.85 | TAS1R3 (0.61) | TAS1R3TAS1R1LNPEP | |
| SCHEMBL701391 | 0.85 | TAS1R3 (0.76) | TAS1R3TAS1R1GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | TAS1R3 989/4885TAS1R1 1141/4885GRN 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.